News | September 17, 2014 IBA, Philips Partner to Advance Cancer Diagnosis, Treatment Agreement to include research and exchange of technologies and solutions to provide access to proton therapy solutions and enhance oncology care centers across the globe News | Radiation Oncology | July 31, 2019 Laura Dawson, M.D., FASTRO, Chosen as ASTRO President-elect The members of the American Society for Radiation Oncology (ASTRO) elected four new officers to ASTRO’s Board of… read more News | Radiation Therapy | August 15, 2019 First Patient Enrolled in World’s Largest Brain Cancer Clinical Trial Henry Ford Cancer Institute is first-in-the-world to enroll a glioblastoma patient in the GBM AGILE Trial (Adaptive… read more Following radiation, the bone marrow shows nearly complete loss of blood cells in mice (left). Mice treated with the PTP-sigma inhibitor displayed rapid recovery of blood cells (purple, right). Credit: UCLA Broad Stem Cell Research Center/Nature Communications News | Proton Therapy | August 06, 2019 IBA Signs Contract to Install Proton Therapy Center in Kansas IBA (Ion Beam Applications S.A.) recently signed a contract and received the first payment for a Proteus One solution… read more Catalyst PT image courtesy of C-RAD News | Patient Positioning Radiation Therapy | August 15, 2019 Mevion and C-RAD Release Integration for Improved Proton Therapy Treatment Quality Mevion Medical Systems and C-RAD announced the integration between the C-RAD Catalyst PT and the Mevion S250i proton… read more News | Patient Positioning Radiation Therapy | August 07, 2019 Qfix kVue One Proton Couch Top Validated by Mevion Medical Systems Qfix and Mevion Medical Systems announced that a special version of the kVue One Proton couch top is now both validated… read more News | Brachytherapy Systems | August 14, 2019 Efficacy of Isoray’s Cesium Blu Showcased in Recent Studies August 14, 2019 — Isoray announced a trio of studies recently reported at scientific meetings and published in medica read more September 17, 2014 — IBA and Philips Healthcare announced the signing of a global collaboration to provide advanced diagnostic and therapeutic solutions for the treatment of cancer.The collaboration covers sales, marketing, research and development (R&D) of imaging and therapy solutions in oncology. By merging their respective expertise in therapy and image guidance systems, IBA and Philips will innovate with an integrated vision for more efficient, personalized cancer care. Leveraging high quality imaging and proton therapy offers the potential to increase confidence in the diagnosis and treatment of cancer, reduce short- and long-term side-effects and potentially enhance the quality of life of the patient before, during and after treatment, while reducing the cost of treatment for the healthcare system.The collaboration will also enable both organizations to mutually leverage technologies and solutions: IBA will benefit from Philips diagnostic imaging products offered to oncology care centers, while Philips will leverage IBA proton therapy solutions within its offering for customers in select markets around the world. The commercial collaboration also includes an integrated offering for molecular imaging centers, combining IBA’s expertise in positron emission tomography (PET) radioisotope production centers with Philips imaging and diagnostics expertise.“This is an exciting and important step for IBA. A closer collaboration with a company of Philips’ caliber and global reach, where we are able to combine both companies’ expertise and excellence in oncology care, will accelerate innovation and provide more efficient and effective solutions in molecular imaging and treatment solutions,” said Olivier Legrain, IBA CEO. “This collaboration is an important step toward adaptive treatment of cancer and a personalized treatment approach to enable the best possible result for cancer patients across the globe.”“Proton therapy is one of the most exciting technological advancements in the oncology field,” said Gene Saragnese, executive vice president and CEO, imaging systems, Philips. “We look forward to collaborating with IBA to enhance access to best-in-class technology for both Proton Centers and Molecular Imaging Centers, as well as to accelerate the development of our informed therapy guidance vision in ways that can change the future of care, and improve the quality of life for patients.”For more information: www.iba-worldwide.com, www.philips.com/newscenter FacebookTwitterLinkedInPrint分享 News | Radiation Therapy | August 16, 2019 Drug Accelerates Blood System’s Recovery After Radiation, Chemotherapy A drug developed by UCLA physician-scientists and chemists speeds up the regeneration of mouse and human blood stem… read more Related Content News | Proton Therapy | August 08, 2019 MD Anderson to Expand Proton Therapy Center The University of Texas MD Anderson Cancer Center unveiled plans to expand its Proton Therapy Center during a… read more Feature | August 05, 2019 | Dave Fornell, Editor Most Popular Radiology and Radiotherapy Topics in July 2019 August 5, 2019 — Here is the list of the most popular content on the Imaging Technology New (ITN) magazine website fr read more News | Radiation Therapy | August 02, 2019 Varian Showcases Cancer Care Systems and Software at AAPM 2019 Varian showcased systems and software from its cancer care portfolio, including the Identify Guidance System, at the… read more The top piece of content in July was a video interview explaining how Princess Margaret Cancer Center is using machine learning to create automated treatment plans. This was a hot topic at the American Association of Physicists in Medicine (AAPM) 2019 meeting in July. The MD Anderson Proton Therapy Center expansion is expected to be completed in 2023. Rendering courtesy of Stantec.